Hims & Hers Health Inc. saw its stock extend gains this week as investors reacted positively to a renewed partnership with pharmaceutical giant Novo Nordisk. HIMS stock gained 3.90% to close at $24.77, capping a remarkable weekly surge of about 57% — the company’s strongest weekly performance since going public. The rally came after the telehealth platform announced it would collaborate with Novo Nordisk to offer blockbuster weight-loss drugs Ozempic and Wegovy on its platform, ending months of legal tension between the two companies.
The San Francisco-based healthcare platform had faced intense scrutiny earlier this year due to legal and regulatory challenges surrounding its weight-loss business. The fresh agreement with Novo Nordisk, however, has shifted investor sentiment dramatically. Analysts say the partnership not only removes a major legal overhang but also provides a clearer growth path for Hims in the booming obesity-drug market.
Novo Nordisk partnership removes major legal overhang
The agreement marks a significant turnaround after a public dispute between the two companies. Novo Nordisk had previously ended its partnership with Hims in June, accusing the telehealth company of engaging in what it called “deceptive marketing” related to compounded versions of its popular GLP-1 drugs. The disagreement escalated further earlier this year when Novo filed a lawsuit against Hims after the company launched a copycat version of a Wegovy pill.
Under the new arrangement, Novo Nordisk has agreed to drop the lawsuit, while Hims will stop advertising compounded versions of Novo’s medications. Instead, the telehealth platform will offer branded Ozempic and Wegovy directly through its digital health platform. Patients will still be able to access copies of the medications if a physician determines they are medically necessary.
The shift effectively resets the relationship between the two companies and removes one of the biggest risks investors had been pricing into the stock. According to analysts, that change alone was enough to spark renewed interest from both institutional investors and retail traders.
More information about the company’s strategy shift in its weight-loss business can be found on the Hims & Hers investor relations page.
Wall Street analysts turn more optimistic
The partnership has already triggered several analyst upgrades. At least four analysts raised their ratings on the stock following the announcement. Investment bank Barclays also increased its price target for Hims shares to $29 from $25 and maintained an Overweight rating, citing improving investor confidence after the Novo Nordisk dispute was resolved.
Barclays analysts said the market may still be underestimating the company’s potential to launch additional healthcare products and expand its digital platform. The fact that HIMS stock rallied sharply after the partnership announcement suggests investors believe the company’s legal challenges are largely behind it.
Needham & Co. analyst Ryan MacDonald also upgraded his recommendation on the stock to Buy from Hold. He said the agreement with Novo Nordisk “alleviated near-term concerns” and could help put the company back on track for long-term growth with the support of a branded pharmaceutical partner.
Still, Wall Street sentiment remains mixed. According to Bloomberg data, only five of the 17 analysts covering the company currently recommend buying the stock, while about eleven maintain Hold ratings. That cautious stance reflects lingering uncertainty about how the company’s evolving weight-loss strategy will affect revenue and profitability.
Transition away from compounded GLP-1 drugs
One of the biggest changes following the agreement is Hims’ decision to shift away from the mass marketing of personalized compounded GLP-1 drugs. These products had been a core part of the company’s weight-loss strategy, allowing doctors to adjust dosage levels or add ingredients to meet specific patient needs.
Citigroup analyst Daniel Grosslight warned that the transition could lead to a “large decline” in revenue and adjusted EBITDA in the near term because compounded drugs often generate higher margins than branded treatments.
However, Grosslight also acknowledged that the deal reduces regulatory and legal risks that had previously weighed on the company. As a result, he upgraded his rating on the stock to Neutral from Sell, signaling a more constructive outlook despite potential short-term financial pressure.
Needham’s MacDonald described the company’s current phase as a “transitionary period.” As Hims moves toward selling more branded medications, analysts say the financial impact will depend on how many existing subscribers shift from compounded drugs to Novo Nordisk’s branded treatments.
“If an existing personalized GLP-1 subscriber transitions to the branded drug, we don’t yet know what the revenue or margin impact will be,” MacDonald said, noting that the company has not disclosed the detailed economics of the partnership.
Stock rebound follows steep earlier losses
The recent rally comes after a difficult period for Hims shareholders. Earlier this year, the company issued a weaker-than-expected profit outlook for the first quarter, sending the stock sharply lower. The situation worsened in February when shares plunged about 46% in a single month — the largest monthly decline in the company’s history.
Before the partnership with Novo Nordisk was announced, HIMS stock had fallen roughly 52% year-to-date and erased about $3.8 billion in market value. The latest surge therefore represents a dramatic turnaround in investor sentiment.
The company has also taken steps to strengthen its leadership team during this transition. This week, Hims hired Kathryn Beiser, former communications chief at Eli Lilly & Co., as its new Chief Communications Officer, a move that analysts believe could help the company navigate regulatory scrutiny and public perception around obesity drugs.
Investors watching the next phase of growth
The obesity-drug market has become one of the most competitive and rapidly growing segments in healthcare, driven by strong demand for GLP-1 treatments that help patients manage weight and diabetes. By partnering with Novo Nordisk, Hims gains access to two of the most widely recognized brands in the category.
For investors, the key question now is whether the company can successfully integrate branded medications into its telehealth ecosystem while maintaining strong subscriber growth and healthy margins. If the transition works, analysts say Hims could emerge as a powerful distribution platform for some of the most sought-after treatments in modern healthcare.
For now, the market’s reaction suggests investors are willing to give the company another chance. With HIMS stock closing at $24.77 after a 3.90% daily gain and a massive 57% weekly rally, the renewed partnership with Novo Nordisk has clearly reignited optimism about the company’s future.
You may also like: IBM Stock Falls 0.40% as Quantum Cybersecurity and Bain Partnership Stay in Focus
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
